5/13/14 17:28 | 5/9/14 | NAVB | Navidea Biopharmaceuticals, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Pykett Mark Jerome | OH | DO | CEO | P | 13 | 1.34 | 1 | 10 | 3 | 297 | D | -51 | -41 | 2 | -18 | -23 | -18 | -12 | -12 | -1 | 9 | 38 | -6 | -11 | -7 |
3/11/14 17:21 | 3/10/14 | NAVB | Navidea Biopharmaceuticals, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Pykett Mark Jerome | OH | DO | CEO | S | -235 | 1.96 | 2 | -120 | -30 | 287 | D | -28 | -38 | -30 | 15 | 18 | 5 | 7 | 10 | 1 | 1 | -16 | -13 | -35 | -22 |
11/8/13 11:46 | 11/8/13 | NAVB | Navidea Biopharmaceuticals, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Pykett Mark Jerome | OH | DO | CEO | P | 15 | 1.35 | 3 | 11 | 3 | 407 | D | -49 | -44 | -43 | -52 | -48 | -36 | -30 | -29 | 9 | 6 | 31 | 25 | 2 | -13 |
3/18/13 14:57 | 3/15/13 | NAVB | Navidea Biopharmaceuticals, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Pykett Mark Jerome | OH | DO | P,CEO | P | 5 | 2.70 | 6 | 2 | 1 | 358 | D | -16 | -16 | 1 | -7 | -20 | -11 | -14 | -22 | 4 | -4 | 0 | -4 | 8 | -23 |
9/14/12 10:41 | 9/11/12 | NAVB | Navidea Biopharmaceuticals, Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Pykett Mark Jerome | OH | DO | P,CEO | P | 11 | 2.64 | 7 | 4 | 1 | 310 | D | 35 | -15 | -17 | -12 | -27 | -31 | -30 | -24 | 6 | 19 | -2 | 8 | 4 | 8 |
8/23/11 08:08 | 8/22/11 | NEOP | Neoprobe Corp | DE | Health | MdEq | Surgical & Medical Instrument | Pykett Mark Jerome | OH | DO | P,CEO | P | 11 | 2.60 | 0 | 4 | New | 4 | M | | | | | | | | | | | | | | |
4/15/08 17:11 | 5/24/04 | ANX | Adventrx Pharmaceuticals Inc | DE | Health | Drug | Pharmaceutical Preparations | Pykett Mark Jerome | CA | D | | P | 1 | 2.08 | 0 | 1 | 7 | 8 | D | -90 | -80 | -34 | 15 | -20 | -2 | -10 | -6 | 0 | 9 | 2 | -23 | -55 | -62 |
4/7/05 14:28 | 4/6/05 | ANX | Adventrx Pharmaceuticals Inc | DE | Health | Drug | Pharmaceutical Preparations | Pykett Mark Jerome | MA | D | | P | 5 | 1.70 | 0 | 3 | New | 3 | D | 274 | -4 | 50 | 76 | 83 | 39 | 24 | 4 | 21 | 40 | 49 | 38 | 112 | 180 |